Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could LVAD patients ditch aspirin? new trial aims to find out

NCT ID NCT07644247

Disease control Sponsor: China National Center for Cardiovascular Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether patients with a heart pump (LVAD) can safely stop taking aspirin while continuing warfarin. The goal is to reduce bleeding problems without increasing dangerous clots. About 370 participants will be randomly assigned to receive either aspirin or a placebo, and researchers will track strokes, pump clots, and major bleeding for one year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
aspirin
What this could lead to
If successful, this could simplify medication for LVAD patients by safely removing aspirin, reducing bleeding risks while still preventing clots.
What could go wrong
This is a Phase 4 trial, but it's not yet recruiting. Removing aspirin might increase the risk of dangerous clots or strokes, and results may not apply to other LVAD devices.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 370 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Study participants must meet all the following criteria: 1. Age ≥18 years old; 2. Implanted with the CH-VAD pump for advanced heart failure, and the CH-VAD pump is the first implanted left ventricular assist device; 3. Able to understand the study purpose, voluntarily participate and sign the informed consent form, and willing to comply with the study procedures and follow-up requirements. Exclusion Criteria: \- Study participants meet any of the following criteria will be excluded: 1. Requirement for additional temporary or permanent mechanical circulatory support after LVAD implantation; 2. Requirement for physician-mandated antiplatelet therapy after implantation due to medical history, surgical history, concomitant surgical procedures, or other conditions, including mandated presence or absence of antiplatelet agent; 3. Occurrence of primary endpoint events prior to randomization (within 2-7 days after implantation); 4. Inability to take oral medications post-implant through 7 days; 5. Known allergy to aspirin; 6. Participation in another clinical investigation that may affect study outcome; 7. Presence of other comorbid conditions, social or psychological conditions, or other conditions, in the investigator's opinion, that may affect participation in the study or compliance with follow-up requirements.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

advanced heart failure Hemorrhage hemorrhagic disease stroke disorder thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antiplatelet therapy Antithrombotic therapy Aspirin Bleeding Hemocompatibility-related adverse event LVAD Lvad (left ventricular assist device) Lvad (left ventricular assist device) thrombosis Lvad-related gi bleed Stroke Thrombosis Ventricular assist device

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.